Notícias e Atividades da Intercept Pharmaceuticals

A Intercept Pharmaceuticals pertence à Alfasigma. Alfasigma tem presença direta em 3 países.

Eles estão dentro:

• Farmacêutica67%
• Biotecnologia33%

Veja o organograma con seus 13 executivos principais

Biografias mais buscadas da Intercept Pharmaceuticals

• Vivek Devaraj, President and Chairman of the Board
• Victoria Carey, Senior Vice President and Head of Strategic Market...
• Sangeeta Sawhney, Senior Vice President and Head of US Research an...

Recentes movimentos de executivos em Alfasigma

• Gabriele Micalella, ingressou na Companhia como Vice President, Procurement, Global Indirect  (Notícia publicada em 19 de março de 2026).

Criar um alerta
para seguir os movimentos de executivos da Intercept Pharmaceuticals.

Alfasigma possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Intercept Pharmaceuticals

• News - Intercept Pharmaceuticals
• News - Intercept Pharmaceuticals
• News - Intercept Pharmaceuticals
• News - Intercept Pharmaceuticals
• https://www.interceptpharma.com/about-us/news/undefined
• Intercept Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update | Intercept Pharmaceuticals, Inc.
• Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022 | Intercept Pharmaceuticals, Inc.
• Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA) | Intercept Pharmaceuticals, Inc.
• Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Outside the U.S. | Intercept Pharmaceuticals, Inc.
• Intercept Announces PBC Data Presentations at The International Liver Congress™ 2022 | Intercept Pharmaceuticals, Inc.
• View more press releases Close

Redes sociais sobre Intercept Pharmaceuticals

• Intercept Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Intercept Pharmaceuticals na LinkedIn, X (Twitter) e YouTube